CD8A and neoplasm: A study has shown that intermittent administration of the PI3Kα/β/δ inhibitor BAY1082439 in a PTEN gene-deficient prostate cancer model can overcome ICT resistance and unleash CD8+ T-cell-dependent anti-tumor immunity.